On January 31, 2025, Clay Siegall, President and Chief Executive Officer of Immunome Inc (IMNM, Financial), purchased 150,000 shares of the company, according to a SEC Filing. Following this transaction, the insider now owns a total of 669,636 shares of the company. Immunome Inc is a biotechnology company focused on developing antibody therapeutics for cancer and infectious diseases. The company's proprietary discovery engine leverages the human immune response to identify and develop novel antibody therapeutics. The recent purchase by the insider is part of a broader trend of insider buying at Immunome Inc. Over the past year, Clay Siegall has acquired a total of 350,000 shares and has not sold any shares. The overall insider transaction history for Immunome Inc shows 7 insider buys and 2 insider sells over the past year. Shares of Immunome Inc were trading at $7.75 each on the day of the insider's recent purchase, giving the stock a market cap of $873.845 million.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
